Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member printed grouped question UIN question first answered answering member label attachment file name title
tabling member	label

Search

386890

	registered interest
	date	01/07/2015
	answering body	Ministry of Defence
	answering dept id	11
	answering dept short name	Defence
	answering dept sort name	Defence
	hansard heading	Defence
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty’s Government over what periods in the last 30 years there has been a threat to the existence of the United Kingdom; and what was the average percentage of gross domestic product spent on defence in each of those years.
	tabling member printed	Lord West of Spithead
	uin	HL999
	answer	answer is ministerial correction date of answer 08/07/2015 answer text <p>The UK has, and continues to face, a broad range of complex threats both at home and abroad.</p><p>The table below shows the proportion of gross domestic product that the UK has spent on defence each year since 1985. This data is published annually by NATO as part of its Defence Expenditure publications.</p><p> </p><table><tbody><tr><td><p><strong>Year</strong></p></td><td><p><strong>Percentage of GDP spent on Defence</strong></p></td></tr><tr><td><p>1985</p></td><td><p>5.2</p></td></tr><tr><td><p>1986</p></td><td><p>4.9</p></td></tr><tr><td><p>1987</p></td><td><p>4.6</p></td></tr><tr><td><p>1988</p></td><td><p>3.2</p></td></tr><tr><td><p>1989</p></td><td><p>4.1</p></td></tr><tr><td><p>1990</p></td><td><p>4.1</p></td></tr><tr><td><p>1991</p></td><td><p>4.3</p></td></tr><tr><td><p>1992</p></td><td><p>3.8</p></td></tr></tbody></table><p> </p><p> </p><table><tbody><tr><td><p>1993</p></td><td><p>3.6</p></td></tr><tr><td><p>1994</p></td><td><p>3.4</p></td></tr><tr><td><p>1995</p></td><td><p>3.1</p></td></tr><tr><td><p>1996</p></td><td><p>3</p></td></tr><tr><td><p>1997</p></td><td><p>2.7</p></td></tr><tr><td><p>1998</p></td><td><p>2.6</p></td></tr><tr><td><p>1999</p></td><td><p>2.5</p></td></tr><tr><td><p>2000</p></td><td><p>2.5</p></td></tr><tr><td><p>2001</p></td><td><p>2.5</p></td></tr><tr><td><p>2002</p></td><td><p>2.4</p></td></tr><tr><td><p>2003</p></td><td><p>2.4</p></td></tr><tr><td><p>2004</p></td><td><p>2.2</p></td></tr><tr><td><p>2005</p></td><td><p>2.5</p></td></tr><tr><td><p>2006</p></td><td><p>2.4</p></td></tr><tr><td><p>2007</p></td><td><p>2.5</p></td></tr><tr><td><p>2008</p></td><td><p>2.6</p></td></tr><tr><td><p>2009</p></td><td><p>2.6</p></td></tr><tr><td><p>2010</p></td><td><p>2.6</p></td></tr><tr><td><p>2011</p></td><td><p>2.6</p></td></tr><tr><td><p>2012</p></td><td><p>2.2</p></td></tr><tr><td><p>2013</p></td><td><p>2.3</p></td></tr><tr><td><p>2014</p></td><td><p>2.2</p></td></tr><tr><td><p>2015</p></td><td><p>2.1</p></td></tr></tbody></table><p> </p> answering member printed Earl Howe question first answered 08/07/2015 15:34:22 answering member 2000 label Biography information for Earl Howe
	tabling member	3834 label Biography information for Lord West of Spithead

77265

	registered interest
	date	10/07/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Lyme Disease
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty’s Government whether, in December 2011, the Clinical Pathology Accreditation Service was made aware of modifications by the Health Protection Agency’s Lyme Borreliosis Unit to the Trinity Biotech immunoblot kit to be used for testing human cerebrospinal fluid.
	tabling member printed	The Countess of Mar
	uin	HL999
	answer	answer is ministerial correction date of answer 24/07/2014 answer text <p>The former Health Protection Agency's Lyme Borreliosis Unit (HPA LBU) was accredited by Clinical Pathology Accreditation who had access to, and was able to review, all the standard operating procedures of the unit.</p><p> </p><p>The Trinity Biotech Lyme Western Blot is a qualitative in vitro assay for the detection of Immunoglobulin (IgG or IgM) antibodies in human samples against specific antigens/proteins of <em>Borrelia afzelii, Borrelia garinii and Borrelia burgdorferi</em>. The Trinity Biotech Lyme Western Blot is intended as a confirmatory assay for use in testing human samples which have been previously found to be positive or equivocal using an Enzyme Immunoassay and Immunofluroescent Assay or other appropriate screening method. Positive second-tier results are supportive evidence of infection with <em>B. burgdorferi</em>. The diagnosis of Lyme disease should be made based on history and symptoms (such as erythema migrans), and other laboratory data, in addition to the presence of antibodies to <em>B. burgdorferi</em>. The Trinity Biotech blot has been in use since 2007 by the former HPA’s LBU for testing cerebrospinal fluid (CSF) and proved very reliable. This technique has also been in use widely across Europe during this period as a diagnostic test using CSF as a sample to support the diagnosis of neuroborreliosis.</p> answering member printed Earl Howe question first answered 24/07/2014 12:32:59 answering member 2000 label Biography information for Earl Howe
	tabling member	1861 label Biography information for The Countess of Mar

386889

	registered interest
	date	01/07/2015
	answering body	Ministry of Defence
	answering dept id	11
	answering dept short name	Defence
	answering dept sort name	Defence
	hansard heading	Iraq: Armed Conflict
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty’s Government what assessment they have made of whether driving Daesh out of Iraq would be a final military victory.
	tabling member printed	Lord West of Spithead
	uin	HL998
	answer	answer is ministerial correction date of answer 07/07/2015 answer text <p>ISIL must be defeated both in Iraq and Syria. This will take time and patience but it is a fight we must win. We are also clear that it cannot be achieved by military action alone which is why the UK supports inclusive governance in Iraq and political transition in Syria.</p> answering member printed Earl Howe question first answered 07/07/2015 16:05:34 answering member 2000 label Biography information for Earl Howe
	tabling member	3834 label Biography information for Lord West of Spithead

77264

	registered interest
	date	10/07/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Lyme Disease
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty’s Government when the testing of the cerebrospinal fluid of patients suspected of having Lyme disease using the Trinity Biotech kit at the Health Protection Agency’s Lyme Borreliosis Unit began; how many patients' samples were tested in that way; and how many patients were recorded as being positive over that period of time.
	tabling member printed	The Countess of Mar
	uin	HL998
	answer	answer is ministerial correction date of answer 24/07/2014 answer text <p>The Trinity Biotech blot has been in use since 2007 by the former Health Protection Agency's Lyme Borreliosis Unit for testing cerebrospinal fluid (CSF) and proved very reliable. It has also been used in this way by other laboratories in Europe. However, CSF antibodies will not be present if there is no evidence of any other antibodies in the serum. Data is not collected centrally on specific samples from patients as the final diagnosis is made by the clinician on the basis of the test results and the clinical presentation.</p> answering member printed Earl Howe question first answered 24/07/2014 12:31:17 answering member 2000 label Biography information for Earl Howe
	tabling member	1861 label Biography information for The Countess of Mar

386888

	registered interest
	date	01/07/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Amyloidosis
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty’s Government which of the four phase 2 or 3 clinical trials for systemic amyloidosis approved since 2004 are still ongoing; and whether any of the trials have produced sufficient positive outcomes to encourage commercial development.
	tabling member printed	Lord Willis of Knaresborough
	uin	HL997
	answer	answer is ministerial correction date of answer 14/07/2015 answer text <p>There are four trials for systemic amyloidosis that are designated as ‘ongoing’ in the United Kingdom. These are being conducted by two commercial sponsors, Millennium Pharmaceuticals Inc and A.T. Development Switzerland Sarl (two studies), and one non-commercial sponsor, European Myeloma Network.</p><p> </p><p> </p><p> </p><p>Clinical trial sponsors are required to publish a summary of their trial results to the EU Clinical Trials Register within one year of their trial completing. At that point, these results will become publically available on the EU Clinical Trials Register</p><p> </p><p> </p><p> </p><p>The Department of Health, which funds the National Institute for Health Research (NIHR), is a member of the National Cancer Research Institute (NCRI). NCRI Clinical Studies Groups (CSGs) bring together clinicians, scientists, statisticians and lay representatives to coordinate development of a strategic portfolio of trials within their field. All CSGs interact with clinical research networks, funders (including NIHR) and researchers to develop studies aimed at improving outcomes for patients. The Haematological Oncology CSG has a Myeloma Subgroup and its 2013-14 annual report that includes an assessment of progress in these areas is attached and available on the NCRI website at:</p><p> </p><p><a href="http://csg.ncri.org.uk/wp-content/uploads/2014/11/NCRI-Haem-Onc-CSG-Annual-Report-2013-14.pdf" target="_blank">http://csg.ncri.org.uk/wp-content/uploads/2014/11/NCRI-Haem-Onc-CSG-Annual-Report-2013-14.pdf</a>.</p><p> </p><p> </p><p> </p><p>We cannot comment on commercial considerations. When the results are known, the commercial potential of these trial’s products will be a matter for the respective trial sponsors.</p><p> </p> answering member printed Lord Prior of Brampton grouped question UIN HL995 HL996 question first answered 14/07/2015 15:34:29 answering member 127 label Biography information for Lord Prior of Brampton attachment 1 file name NCRI-Haem-Onc-CSG-Annual-Report-2013-14.pdf title 2013-14 Annual Report
	tabling member	4151 label Biography information for Lord Willis of Knaresborough

77263

	registered interest
	date	10/07/2014
	answering body	Home Office
	answering dept id	1
	answering dept short name	Home Office
	answering dept sort name	Home Office
	hansard heading	Harmondsworth Immigration Removal Centre
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government whether, following the Independent Monitoring Board's Annual Report 2013, they have initiated changes at Harmondsworth Immigration Removal Centre to ensure that detainees claiming to be under 18 are assessed by social services in the community rather than in the centre.
	tabling member printed	Baroness Stern
	uin	HL997
	answer	answer is ministerial correction date of answer 23/07/2014 answer text <p>The Independent Monitoring Board (IMB) for Harmondsworth published its 2013 report on 30 June. An action plan to address the recommendations in the report will be agreed by 11 August. Plans to make changes to the configuration of the healthcare unit to address the provision of appropriate accommodation for those with mental health or behavioural problems are under discussion with the new healthcare provider at Harmondsworth. This is in advance of the transfer of healthcare commissioning to NHS England on 1 September. Individuals who claim to be under the age of 18 following their detention are managed in accordance with Detention Services Order 14/2012 for the care and management of age dispute cases. This sets out the policy and procedures to follow in individual cases where there is a lack of physical or definitive documentary evidence to prove the person is under the age of 18. This also details the circumstances in which release by case owners is appropriate.</p> answering member printed Lord Taylor of Holbeach question first answered 23/07/2014 13:10:51 answering member 3787 label Biography information for Lord Taylor of Holbeach
	tabling member	2475 label Biography information for Baroness Stern

386887

	registered interest
	date	01/07/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Amyloidosis
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty’s Government whether there are currently any trials for systemic amyloidosis in humans being conducted by the National Institute of Health Research charities or the commercial sector.
	tabling member printed	Lord Willis of Knaresborough
	uin	HL996
	answer	answer is ministerial correction date of answer 14/07/2015 answer text <p>There are four trials for systemic amyloidosis that are designated as ‘ongoing’ in the United Kingdom. These are being conducted by two commercial sponsors, Millennium Pharmaceuticals Inc and A.T. Development Switzerland Sarl (two studies), and one non-commercial sponsor, European Myeloma Network.</p><p> </p><p> </p><p> </p><p>Clinical trial sponsors are required to publish a summary of their trial results to the EU Clinical Trials Register within one year of their trial completing. At that point, these results will become publically available on the EU Clinical Trials Register</p><p> </p><p> </p><p> </p><p>The Department of Health, which funds the National Institute for Health Research (NIHR), is a member of the National Cancer Research Institute (NCRI). NCRI Clinical Studies Groups (CSGs) bring together clinicians, scientists, statisticians and lay representatives to coordinate development of a strategic portfolio of trials within their field. All CSGs interact with clinical research networks, funders (including NIHR) and researchers to develop studies aimed at improving outcomes for patients. The Haematological Oncology CSG has a Myeloma Subgroup and its 2013-14 annual report that includes an assessment of progress in these areas is attached and available on the NCRI website at:</p><p> </p><p><a href="http://csg.ncri.org.uk/wp-content/uploads/2014/11/NCRI-Haem-Onc-CSG-Annual-Report-2013-14.pdf" target="_blank">http://csg.ncri.org.uk/wp-content/uploads/2014/11/NCRI-Haem-Onc-CSG-Annual-Report-2013-14.pdf</a>.</p><p> </p><p> </p><p> </p><p>We cannot comment on commercial considerations. When the results are known, the commercial potential of these trial’s products will be a matter for the respective trial sponsors.</p><p> </p> answering member printed Lord Prior of Brampton grouped question UIN HL995 HL997 question first answered 14/07/2015 15:34:29 answering member 127 label Biography information for Lord Prior of Brampton attachment 1 file name NCRI-Haem-Onc-CSG-Annual-Report-2013-14.pdf title 2013-14 Annual Report
	tabling member	4151 label Biography information for Lord Willis of Knaresborough

77262

	registered interest
	date	10/07/2014
	answering body	Home Office
	answering dept id	1
	answering dept short name	Home Office
	answering dept sort name	Home Office
	hansard heading	Harmondsworth Immigration Removal Centre
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government what plans they have to respond to the Independent Monitoring Board's Annual Report 2013 on Harmondsworth Immigration Removal Centre and in particular its finding in respect of the provision of appropriate accommodation for those with mental health or behavioural problems.
	tabling member printed	Baroness Stern
	uin	HL996
	answer	answer is ministerial correction date of answer 22/07/2014 answer text <p>The Independent Monitoring Board (IMB) for Harmondsworth published its 2013 report on 30 June. An action plan to address the recommendations in the report will be agreed by 11 August. Plans to make changes to the configuration of the healthcare unit to address the provision of appropriate accommodation for those with mental health or behavioural problems are under discussion with the new healthcare provider at Harmondsworth. This is in advance of the transfer of healthcare commissioning to NHS England on 1 September. Individuals who claim to be under the age of 18 following their detention are managed in accordance with Detention Services Order 14/2012 for the care and management of age dispute cases. This sets out the policy and procedures to follow in individual cases where there is a lack of physical or definitive documentary evidence to prove the person is under the age of 18. This also details the circumstances in which release by case owners is appropriate.</p> answering member printed Lord Taylor of Holbeach question first answered 22/07/2014 17:28:25 answering member 3787 label Biography information for Lord Taylor of Holbeach
	tabling member	2475 label Biography information for Baroness Stern

386886

	registered interest
	date	01/07/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Amyloidosis and Multiple Myeloma
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty’s Government whether they will place in the Library of the House any publications resulting from the phase 3 clinical trials approved for the potential treatment of systemic amyloidosis or multiple myeloma; and what is the National Institute of Health Research’s assessment of progress in these areas.
	tabling member printed	Lord Willis of Knaresborough
	uin	HL995
	answer	answer is ministerial correction date of answer 14/07/2015 answer text <p>There are four trials for systemic amyloidosis that are designated as ‘ongoing’ in the United Kingdom. These are being conducted by two commercial sponsors, Millennium Pharmaceuticals Inc and A.T. Development Switzerland Sarl (two studies), and one non-commercial sponsor, European Myeloma Network.</p><p> </p><p> </p><p> </p><p>Clinical trial sponsors are required to publish a summary of their trial results to the EU Clinical Trials Register within one year of their trial completing. At that point, these results will become publically available on the EU Clinical Trials Register</p><p> </p><p> </p><p> </p><p>The Department of Health, which funds the National Institute for Health Research (NIHR), is a member of the National Cancer Research Institute (NCRI). NCRI Clinical Studies Groups (CSGs) bring together clinicians, scientists, statisticians and lay representatives to coordinate development of a strategic portfolio of trials within their field. All CSGs interact with clinical research networks, funders (including NIHR) and researchers to develop studies aimed at improving outcomes for patients. The Haematological Oncology CSG has a Myeloma Subgroup and its 2013-14 annual report that includes an assessment of progress in these areas is attached and available on the NCRI website at:</p><p> </p><p><a href="http://csg.ncri.org.uk/wp-content/uploads/2014/11/NCRI-Haem-Onc-CSG-Annual-Report-2013-14.pdf" target="_blank">http://csg.ncri.org.uk/wp-content/uploads/2014/11/NCRI-Haem-Onc-CSG-Annual-Report-2013-14.pdf</a>.</p><p> </p><p> </p><p> </p><p>We cannot comment on commercial considerations. When the results are known, the commercial potential of these trial’s products will be a matter for the respective trial sponsors.</p><p> </p> answering member printed Lord Prior of Brampton grouped question UIN HL996 HL997 question first answered 14/07/2015 15:34:29 answering member 127 label Biography information for Lord Prior of Brampton attachment 1 file name NCRI-Haem-Onc-CSG-Annual-Report-2013-14.pdf title 2013-14 Annual Report
	tabling member	4151 label Biography information for Lord Willis of Knaresborough

77261

	registered interest
	date	10/07/2014
	answering body	Department for Culture Media and Sport
	answering dept id	10
	answering dept short name	Culture, Media and Sport
	answering dept sort name	Culture, Media and Sport
	hansard heading	Gambling
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government what is the estimated average number of licence applications that a single operator of a sports book, online casino, poker room or gambling software provider would need to submit in order to comply fully with Gambling Commission licensing requirements.
	tabling member printed	Lord Mancroft
	uin	HL995
	answer	answer is ministerial correction date of answer 17/07/2014 answer text <p>Gambling operators can make one application to the Gambling Commission for multiple activities.</p> answering member printed Lord Gardiner of Kimble question first answered 17/07/2014 14:20:48 answering member 4161 label Biography information for Lord Gardiner of Kimble
	tabling member	1833 label Biography information for Lord Mancroft